Cephalexin is a first-generation cephalosporin with an antibacterial spectrum similar to that of cephalothin, but its antibacterial activity is poorer than that of the latter. Except for Enterococcus and methicillin-resistant Staphylococci, most strains of Streptococcus pneumoniae, hemolytic Streptococcus, and Staphylococcus aureus that produces or does not produce penicillinase are sensitive to this product. This product has a good antibacterial effect on Neisseria, but Haemophilus influenzae is less sensitive to this product; this product has a certain antibacterial effect on some Escherichia coli, Proteus mirabilis, Salmonella and Shigella. The remaining Enterobacteriaceae, Acinetobacter, Pseudomonas aeruginosa, and Bacteroides fragilis are resistant to this product. Fusobacterium and Veillonella are generally sensitive to this product, and anaerobic Gram-positive cocci are moderately sensitive to this product. The oral median lethal dose of cephalexin in mice is 2600 mg/kg.

Extract from the above information

This product is a first-generation cephalosporin, which has good antibacterial effect on some strains of Gram-positive cocci such as non-penicillinase-producing and penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococci, group A hemolytic streptococci, Streptococcus pneumoniae and viridans streptococci. Anaerobic Gram-positive bacteria are mostly sensitive to this product, and Bacteroides fragilis is resistant to this product. Methicillin-resistant Staphylococci and Enterococci are resistant to this product. The effect of this product on Gram-positive and Gram-negative bacteria is similar to that of cephalexin. This product has a certain effect on gonococci and is also active against enzyme-producing gonococci; its activity against Haemophilus influenzae is poor.

Doxazosin is a selective α-receptor blocker. It selectively and competitively blocks postganglionic α1-adrenergic receptors to dilate blood vessels, reduce vascular resistance, and lower blood pressure. Doxazosin is an effective blocker of the A1 subtype of α1-adrenergic receptors, and more than 70% of prostate α1 receptors are A1 subtypes. Therefore, it can improve the symptoms of benign prostatic hyperplasia by selectively blocking α1-adrenergic receptors (mainly A1 subtypes) located in the matrix, capsule, and bladder neck smooth muscle. Doxazosin can moderately increase the ratio of high-density lipoprotein cholesterol to total cholesterol, but its clinical significance has not yet been determined. In vitro studies have shown that 5μmol of doxazosin 6,- and 7,-hydroxylated metabolites have antioxidant effects.

This product belongs to the macrolide antibiotics. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), all groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, certain spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on certain bacteria at high concentrations. It can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site ("P" site), blocking the transfer RNA (t-RNA) from binding to the "P" site, and also blocking the self-acceptor site ("A" site) of the polypeptide chain.